Bryce D Smith1, Anthony K Yartel2, Katherine Krauskopf3, Omar I Massoud4, Kimberly A Brown5, Michael B Fallon6, David B Rein7. 1. Division of Viral Hepatitis, Centers for Disease Control and Prevention. 2. Centers for Disease Control and Prevention Foundation, Atlanta, Georgia. 3. Icahn School of Medicine at Mount Sinai, New York, New York. 4. University of Alabama at Birmingham. 5. Henry Ford Hospital, Detroit, Michigan. 6. University of Texas at Houston. 7. NORC at the University of Chicago, Illinois.
Abstract
BACKGROUND: Hepatitis C virus (HCV) testing guidance issued by the Centers for Disease Control and Prevention in 1998 recommends HCV antibody (anti-HCV) testing for persons with specified risk factors. The purpose of this study was to determine the prevalence and predictors of anti-HCV positivity among primary care outpatients and estimate the proportion of unidentified anti-HCV-positive (anti-HCV+) persons using risk-based testing. METHODS: We analyzed electronic medical record data from a 4-site retrospective study. Patients were aged ≥18 years, utilized ≥1 outpatient primary care service(s) between 2005 and 2010, and had no documented evidence of prior HCV diagnosis. Among persons tested for anti-HCV, we fit a multilevel logistic regression model to identify patient-level independent predictors of anti-HCV positivity. We estimated the proportion of unidentified anti-HCV+ persons by using multiple imputation to assign anti-HCV results to untested patients. RESULTS: We observed 209 076 patients for a median of 5 months (interquartile range, 1-23 months). Among 17 464 (8.4%) patients who were tested for anti-HCV, 6.4% (n=1115) were positive. We identified history of injection drug use (adjusted odds ratio [95% confidence interval], 6.3 [5.2-7.6]), 1945-1965 birth cohort (4.4 [3.8-5.1]), and elevated alanine aminotransferase levels (4.8 [4.2-5.6]) as independently associated with anti-HCV positivity. We estimated that 81.5% (n=4890/6005) of anti-HCV+ patients were unidentified using risk-based testing. CONCLUSIONS: In these outpatient primary care settings, risk-based testing may have missed 4 of 5 newly enrolled patients who are anti-HCV+. Without knowing their status, unidentified anti-HCV+ persons cannot receive further clinical evaluation or antiviral treatment, and are unlikely to benefit from secondary prevention recommendations to limit disease progression and mortality. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND:Hepatitis C virus (HCV) testing guidance issued by the Centers for Disease Control and Prevention in 1998 recommends HCV antibody (anti-HCV) testing for persons with specified risk factors. The purpose of this study was to determine the prevalence and predictors of anti-HCV positivity among primary care outpatients and estimate the proportion of unidentified anti-HCV-positive (anti-HCV+) persons using risk-based testing. METHODS: We analyzed electronic medical record data from a 4-site retrospective study. Patients were aged ≥18 years, utilized ≥1 outpatient primary care service(s) between 2005 and 2010, and had no documented evidence of prior HCV diagnosis. Among persons tested for anti-HCV, we fit a multilevel logistic regression model to identify patient-level independent predictors of anti-HCV positivity. We estimated the proportion of unidentified anti-HCV+ persons by using multiple imputation to assign anti-HCV results to untested patients. RESULTS: We observed 209 076 patients for a median of 5 months (interquartile range, 1-23 months). Among 17 464 (8.4%) patients who were tested for anti-HCV, 6.4% (n=1115) were positive. We identified history of injection drug use (adjusted odds ratio [95% confidence interval], 6.3 [5.2-7.6]), 1945-1965 birth cohort (4.4 [3.8-5.1]), and elevated alanine aminotransferase levels (4.8 [4.2-5.6]) as independently associated with anti-HCV positivity. We estimated that 81.5% (n=4890/6005) of anti-HCV+ patients were unidentified using risk-based testing. CONCLUSIONS: In these outpatient primary care settings, risk-based testing may have missed 4 of 5 newly enrolled patients who are anti-HCV+. Without knowing their status, unidentified anti-HCV+ persons cannot receive further clinical evaluation or antiviral treatment, and are unlikely to benefit from secondary prevention recommendations to limit disease progression and mortality. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Entities:
Keywords:
HCV testing; anti-HCV prevalence; hepatitis C virus (HCV); outpatient primary care; predictors of HCV positivity
Authors: David B Rein; John S Wittenborn; Cindy M Weinbaum; Miriam Sabin; Bryce D Smith; Sarah B Lesesne Journal: Dig Liver Dis Date: 2010-06-17 Impact factor: 4.088
Authors: Bryce D Smith; Rebecca L Morgan; Geoff A Beckett; Yngve Falck-Ytter; Deborah Holtzman; Chong-Gee Teo; Amy Jewett; Brittney Baack; David B Rein; Nita Patel; Miriam Alter; Anthony Yartel; John W Ward Journal: MMWR Recomm Rep Date: 2012-08-17
Authors: Brian J McMahon; Dana Bruden; Michael G Bruce; Stephen Livingston; Carol Christensen; Chriss Homan; Thomas W Hennessy; James Williams; Daniel Sullivan; Hugo R Rosen; David Gretch Journal: Gastroenterology Date: 2009-11-10 Impact factor: 22.682
Authors: Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C Gordon; Michael Schultz; Mitchell N Davis; Zeid Kayali; K Rajender Reddy; Ira M Jacobson; Kris V Kowdley; Lisa Nyberg; G Mani Subramanian; Robert H Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Aasim M Sheikh; Zobair Younossi; Edward J Gane Journal: N Engl J Med Date: 2013-04-23 Impact factor: 91.245
Authors: Adriaan J van der Meer; Bart J Veldt; Jordan J Feld; Heiner Wedemeyer; Jean-François Dufour; Frank Lammert; Andres Duarte-Rojo; E Jenny Heathcote; Michael P Manns; Lorenz Kuske; Stefan Zeuzem; W Peter Hofmann; Robert J de Knegt; Bettina E Hansen; Harry L A Janssen Journal: JAMA Date: 2012-12-26 Impact factor: 56.272
Authors: Andrew D Schreiner; John Bian; Jingwen Zhang; Z Merle Haulsee; Justin Marsden; Valerie Durkalski-Mauldin; Patrick D Mauldin; William P Moran; Don C Rockey Journal: Am J Med Date: 2019-07-29 Impact factor: 4.965
Authors: Anthony K Yartel; David B Rein; Kimberly Ann Brown; Katherine Krauskopf; Omar I Massoud; Cynthia Jordan; Natalie Kil; Alex D Federman; David R Nerenz; Joanne E Brady; Danielle L Kruger; Bryce D Smith Journal: Hepatology Date: 2018-01-02 Impact factor: 17.425
Authors: Anthony K Yartel; Rebecca L Morgan; David B Rein; Kimberly Ann Brown; Natalie B Kil; Omar I Massoud; Michael B Fallon; Bryce D Smith Journal: Am J Prev Med Date: 2015-04-18 Impact factor: 5.043
Authors: Joanne E Brady; Danielle K Liffmann; Anthony Yartel; Natalie Kil; Alex D Federman; Joseph Kannry; Cynthia Jordan; Omar I Massoud; David R Nerenz; Kimberly A Brown; Bryce D Smith; Claudia Vellozzi; David B Rein Journal: Hepatology Date: 2016-11-25 Impact factor: 17.425
Authors: David B Rein; John S Wittenborn; Bryce D Smith; Danielle K Liffmann; John W Ward Journal: Clin Infect Dis Date: 2015-03-16 Impact factor: 9.079
Authors: Alex D Federman; Natalie Kil; Joseph Kannry; Evie Andreopolous; Wilma Toribio; Joanne Lyons; Mark Singer; Anthony Yartel; Bryce D Smith; David B Rein; Katherine Krauskopf Journal: Med Care Date: 2017-06 Impact factor: 2.983